Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion

被引:73
作者
Chevreau, C
Mazerolles, C
Soulié, M
Gaspard, MH
Mourey, L
Bujan, L
Plante, P
Rischmann, P
Bachaud, JM
Malavaud, B
机构
[1] CHU Rangueil, Dept Urol, F-31403 Toulouse, France
[2] CHU Rangueil, Dept Pathol, F-31403 Toulouse, France
[3] Inst Claudius Regaud, Dept Med Oncol, F-31052 Toulouse, France
[4] CHU Toulouse Paule Viguier, Dept Reprod Med, CECOS, Toulouse, France
关键词
stage INSGCT; adjuvant chemotherapy; BEP; fertility;
D O I
10.1016/j.eururo.2004.03.022
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To report the long-term impact of two cycles of adjuvant chemotherapy on relapse rates and treatment-related morbidity in high-risk stage I nonseminomatous testicular germ cell tumors (NSGCTT 1). Material and Methods: From April 1987 to September 1997, 40 stage I NSGCTT patients with evidence of vascular invasion and/or embryonal carcinoma (EC) in the orchidectomy specimen were treated with two courses of bleomycin, cisplatin, and etoposide (BEP). Results: All patients but one (incidental death) were alive after an extended follow-up (median 113.2 months, range 63-189). No patients relapsed but two patients presented a second cancer in the remaining testis. Short-term toxicity was minimal and no long-term toxicity was observed. Conclusion: The present series, with extensive follow-up, demonstrated that the efficacy and toxicity of two cycles of BEP compared well with the results of surveillance strategies or RPLND in high-risk stage I NSGCTT. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 50 条
[31]  
MIETTINEN M, 1994, MODERN PATHOL, V7, P82
[32]   TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
OKEN, MM ;
CREECH, RH ;
TORMEY, DC ;
HORTON, J ;
DAVIS, TE ;
MCFADDEN, ET ;
CARBONE, PP .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06) :649-655
[33]   PILOT-STUDY TO EVALUATE IMPACT OF A POLICY OF ADJUVANT CHEMOTHERAPY FOR HIGH-RISK STAGE-1 MALIGNANT TERATOMA ON OVERALL RELAPSE RATE OF STAGE-1 CANCER-PATIENTS [J].
OLIVER, RTD ;
RAJA, MA ;
ONG, J ;
GALLAGHER, CJ .
JOURNAL OF UROLOGY, 1992, 148 (05) :1453-1456
[34]   OBSERVATION AFTER ORCHIECTOMY IN CLINICAL STAGE-I NONSEMINOMATOUS GERM-CELL TUMOR OF TESTIS - MAYO CLINIC EXPERIENCE [J].
PATEL, SR ;
RICHARDSON, RL ;
KVOLS, L ;
ZINCKE, H .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (05) :379-381
[35]   ORCHIECTOMY ALONE IN CLINICAL STAGE-I NONSEMINOMATOUS TESTIS CANCER - A CRITICAL-APPRAISAL [J].
PIZZOCARO, G ;
ZANONI, F ;
MILANI, A ;
SALVIONI, R ;
PIVA, L ;
PILOTTI, S ;
BOMBARDIERI, E ;
TESOROTESS, JD ;
MUSUMECI, R .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (01) :35-40
[36]   Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: Long-term results of a prospective trial [J].
Pont, J ;
Albrecht, W ;
Postner, G ;
Sellner, F ;
Angel, K ;
Holtl, W .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :441-448
[37]   SURVEILLANCE FOR STAGE-I NON-SEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - THE OPTIMAL PROTOCOL HAS NOT YET BEEN DEFINED [J].
RAGHAVAN, D ;
COLLS, B ;
LEVI, J ;
FITZHARRIS, B ;
TATTERSALL, MHN ;
ATKINSON, C ;
WOODS, R ;
COOREY, G ;
FARRELL, C ;
WINES, R .
BRITISH JOURNAL OF UROLOGY, 1988, 61 (06) :522-526
[38]   MEDICAL-RESEARCH-COUNCIL PROSPECTIVE-STUDY OF SURVEILLANCE FOR STAGE-I TESTICULAR TERATOMA [J].
READ, G ;
STENNING, SP ;
CULLEN, MH ;
PARKINSON, MC ;
HORWICH, A ;
KAYE, SB ;
COOK, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1762-1768
[39]  
SCHMOLL HJ, IN PRESS ANN ONCOL
[40]  
Schrader A. J., 2004, European Urology Supplements, V3, P165, DOI 10.1016/S1569-9056(04)90644-6